Ozempic causes weight loss through several overlapping mechanisms: it suppresses appetite by acting on hunger circuits in the brain, slows digestion so you feel full longer, and shifts how your body handles blood sugar and fat storage. The active ingredient, semaglutide, mimics a natural gut hormone called GLP-1 that your body already produces after meals. But the drug version is engineered to last much longer in your system, amplifying effects that normally fade within minutes.
In the landmark STEP 1 clinical trial, people taking semaglutide lost an average of 14.9% of their body weight over 68 weeks, compared to just 2.4% in the placebo group. That’s a striking difference, and it comes down to how the drug works on multiple systems at once.
It Mimics a Gut Hormone Your Body Already Makes
When you eat, your intestines release GLP-1 (glucagon-like peptide-1), a hormone that signals your brain to feel satisfied and tells your pancreas to release insulin. Natural GLP-1 breaks down in your bloodstream within a few minutes. Semaglutide is 94% identical to human GLP-1 but has been chemically modified so your body can’t break it down as quickly. That’s why one weekly injection keeps the drug active for days instead of minutes.
Once semaglutide binds to GLP-1 receptors throughout your body, it triggers a cascade of internal signals inside cells. These signals affect insulin release, blood sugar regulation, and communication between your gut and brain. The result is a sustained version of the “I’m full” signal that naturally occurs after a meal, except it doesn’t fade nearly as fast.
How It Changes Your Appetite at the Brain Level
The most powerful weight loss effect comes from the brain. Semaglutide activates GLP-1 receptors in the hypothalamus, the region that regulates hunger and thirst. NIH researchers have mapped a specific neural circuit in this area that, when activated by GLP-1 receptor agonists, produces appetite suppression and weight loss. This isn’t just willpower or feeling slightly less hungry. People on the drug consistently report a fundamental shift in how they think about food: cravings quiet down, the urge to snack between meals diminishes, and portion sizes naturally shrink.
This brain-level effect is why semaglutide works differently from older weight loss approaches that targeted metabolism or fat absorption. It changes the drive to eat at its source, making it easier to consume fewer calories without the constant feeling of deprivation that derails most diets.
Your Stomach Empties More Slowly
Semaglutide also slows down how fast food leaves your stomach, a process called gastric emptying. When food sits in your stomach longer, you physically feel full for an extended period after eating. In one controlled trial of a similar GLP-1 drug, 57% of patients developed measurably delayed gastric emptying. For about half of those people, the delay persisted through 16 weeks of treatment, while the other half saw their digestion normalize over time.
This slower digestion is a double-edged sword. It contributes meaningfully to feeling satisfied on smaller meals, but it’s also the main reason for the drug’s most common side effects. Nausea, vomiting, diarrhea, abdominal pain, and constipation each affect at least 5% of patients. Gastrointestinal side effects occurred in about 31% to 34% of patients depending on dose, though only around 3% to 4% found them severe enough to stop treatment. Studies using endoscopy have found that people on semaglutide are significantly more likely to have residual food in their stomachs compared to those not on the drug (24% versus 5%).
Effects on Blood Sugar and Fat Storage
Ozempic was originally developed for type 2 diabetes, and its metabolic effects contribute to weight loss even in people without diabetes. The drug increases insulin secretion when blood sugar is elevated after a meal, which helps shuttle glucose into cells for energy rather than allowing it to linger in the bloodstream. At the same time, it suppresses glucagon, a hormone that tells your liver to release stored sugar. The net effect is tighter blood sugar control with less of the insulin spikes that promote fat storage.
One important safety feature: semaglutide only boosts insulin when blood sugar is actually high. This glucose-dependent action means it rarely causes dangerously low blood sugar, unlike some older diabetes medications. There’s also evidence the drug helps reduce fat accumulation in the liver and lower inflammation, which may have benefits beyond weight loss alone.
What the Weight Loss Actually Looks Like
Treatment starts with a low dose of 0.25 mg per week, which isn’t even considered a therapeutic dose. It exists solely to let your body adjust and minimize nausea. The dose gradually increases over several weeks, with a maximum recommended dose of 2 mg weekly. You inject it once a week on the same day, at any time, with or without food.
The 14.9% average weight loss seen in clinical trials translates to roughly 30 to 35 pounds for someone starting at 230 pounds. But that average masks a wide range of individual responses. Some people lose considerably more, while others see modest results. The weight loss also isn’t purely fat. In the STEP 1 trial, lean mass (which includes muscle) accounted for about 45% of the total weight lost. That’s notably higher than the general rule of thumb that about one quarter of weight loss comes from lean tissue. This has raised concerns about muscle loss, particularly in older adults, and is one reason resistance training is strongly encouraged alongside the medication.
What Happens If You Stop Taking It
Semaglutide doesn’t permanently reset your body’s weight set point. A systematic review published in The Lancet found that after stopping GLP-1 receptor agonists, people regain an estimated 75% of the weight they lost, with regain plateauing beyond 52 weeks off the drug. So if you lost 30 pounds, you could expect to regain roughly 22 of them within a year or so of stopping.
This isn’t a flaw unique to Ozempic. It reflects the biology of obesity itself: the brain and hormonal systems that regulate body weight actively push back against sustained weight loss, regardless of how the loss was achieved. For most people, semaglutide works best as an ongoing treatment rather than a short course, which has significant implications for cost and long-term planning.
Cardiovascular Benefits Beyond Weight Loss
The SELECT trial found that semaglutide reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in people with obesity and established heart disease. Interestingly, only about a third of that benefit was explained by reductions in waist circumference. The cardioprotective effects appeared independent of how much weight someone lost or how heavy they were at the start, suggesting semaglutide has direct effects on the cardiovascular system that go beyond simply making people lighter.